Division of Gynaecological Oncology, Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Department of Radiation-Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Gynecol Oncol. 2021 Sep;162(3):539-545. doi: 10.1016/j.ygyno.2021.06.026. Epub 2021 Jul 10.
Lymphovascular space invasion (LVSI), deep (>1/3) stromal invasion (DSI) and large tumor size (>4 cm) have been identified as predictors for intermediate risk for recurrence according to Sedlis (at least two of the prior risk factors) in FIGO stage I cervical cancer. Adjuvant radiotherapy (RT) has been advocated in these patients(1,2), but remains controversial.
All consecutive patients (1997-2017) with cervical cancer FIGO (2009) stage IB1 (≤4 cm) were included. Primary aim was to analyze the recurrence rate. Secondary aim was to identify the risk factors for disease recurrence and survival.
One-hundred-and-eighty-two patients were included in this retrospective study. Median follow-up was 13 years (range 8-17). Postoperatively, 21 patients received adjuvant therapy due to presence of positive lymph nodes, positive section margins or if a simple hysterectomy was performed (RT: n = 7, concomitant chemo radiotherapy (CCRT): n = 14). None of the patients with a combination of intermediate risk factors according to Sedlis (excluding patients >4 cm) underwent adjuvant RT/CCRT. Disease recurrence was observed in 19 patients (10%). Eleven patients died of disease. LVSI influenced progression-free survival (PFS) (HR 3.950, p = 0.0163) and disease-specific survival (DSS) (HR 4.637, p = 0.0497) significantly. However, the combination of LVSI, tumor size and DSI according to Sedlis did not influence overall survival (OS), DSS or PFS.
Recurrence rate was low (10%), despite the fact that patients with intermediate risk factors according to Sedlis did not receive postoperative RT/CCRT. LVSI was the sole risk factor influencing PFS and DSS. Combinations of risk factors according to Sedlis did not predict worse outcome.
淋巴血管空间侵犯(LVSI)、深层(>1/3)间质浸润(DSI)和大肿瘤尺寸(>4cm)已被确定为 Sedlis 标准中 FIGO 分期 I 期宫颈癌复发的中危预测因素(至少存在上述两个高危因素)。(1,2)在这些患者中主张辅助放疗(RT),但仍存在争议。
所有连续的宫颈癌 FIGO(2009)IB1 期(≤4cm)患者(1997-2017 年)均纳入本回顾性研究。主要目的是分析复发率。次要目的是确定疾病复发和生存的危险因素。
本研究共纳入 182 例患者。中位随访时间为 13 年(8-17 年)。术后,由于存在阳性淋巴结、阳性切片边缘或单纯子宫切除术,21 例患者接受了辅助治疗(RT:n=7,同期放化疗(CCRT):n=14)。没有 Sedlis 标准中存在中危因素的患者(不包括>4cm 的患者)接受了辅助 RT/CCRT。19 例患者(10%)出现疾病复发。11 例患者死于疾病。LVSI 显著影响无进展生存(PFS)(HR 3.950,p=0.0163)和疾病特异性生存(DSS)(HR 4.637,p=0.0497)。然而,Sedlis 标准中的 LVSI、肿瘤大小和 DSI 组合并未影响总生存(OS)、DSS 或 PFS。
尽管 Sedlis 标准中有中危因素的患者未接受术后 RT/CCRT,但复发率仍较低(10%)。LVSI 是唯一影响 PFS 和 DSS 的危险因素。Sedlis 标准中的风险因素组合并不能预测更差的结局。